• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
    • Overview
    • Distribution by PR Newswire
    • Cision Communications Cloud®
    • Cision IR
    • All Products
  • Contact
    • General Inquiries
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

Biofourmis Announces Acquisition of Biovotion AG, Completing Biovitals® Platform to Deliver Precise Interventions at the Right Time to Manage Patients with Complex Chronic Conditions

Acquisition of Biovotion establishes Biovitals® as the most comprehensive predictive digital therapeutics solution for healthcare providers, payers and pharmaceutical companies by combining best-in-class medical data collection and digital therapeutics solutions into one platform

Biofourmis is a fast-growing global health IT start-up founded in Singapore, with U.S. offices in Boston, that augments personalized patient care and therapies with Digital Therapeutics for better management of patients with complex chronic conditions. (PRNewsfoto/Biofourmis)

News provided by

Biofourmis

Nov 18, 2019, 07:00 ET

Share this article

Share this article


BOSTON and ZÜRICH, Nov. 18, 2019 /PRNewswire/ -- Biofourmis, a fast-growing global leader in digital therapeutics based in Boston, announced today it has reached an agreement to acquire Zürich, Switzerland-based Biovotion AG, a leading developer of a cutting-edge clinical-grade wearable biosensor platform. The acquisition includes all of Biovotion's assets, including the market-leading Everion® biosensor and more than 60 global patents covering most of the wearable and sensor technology that exists for the arm or hand.

The acquisition of Biovotion enables Biofourmis to offer proprietary, clinical-grade wearables as part of its Biovitals® ecosystem. Clinical-grade wearables are becoming integral across all areas of healthcare, offering continuous real-time physiological data formerly only available in clinical settings. Combining Biovotion's best-in-class wearables with Biofourmis' digital therapeutics platform and its leading artificial intelligence (AI)-driven predictive analytics creates the most comprehensive digital therapeutics solution on the market.

Biofourmis' clinically validated and FDA-approved software-based digital therapeutics that are part of the growing Biovitals® ecosystem are already being leveraged across multiple segments of healthcare and life sciences to predict and prevent adverse health events and to provide better outcomes for patients; to deliver personalized care and manage chronic conditions such as heart failure, COPD and coronary artery disease; to demonstrate the value of and potentially complement pharmacotherapy; to provide cost-effective solutions for payers; and to advance clinical research.

The lead product among Biovotion's wearables is the clinical-grade Everion® device, which is a multi-sensor platform worn on the arm capable of measuring 22 parameters in real time. Collected physiological data can include heart rate, inter-beat interval, respiratory rate, blood oxygenation, skin temperature and actigraphy (rest/activity cycles)—all gathered non-invasively. Additional clinical and non-clinical parameters such as blood pulse wave, motion intensity and steps, energy expenditure, sleep quality and heart rate variability are also insights collected by Everion®. Building on Everion's current market-leading wearable, the next-generation Everion® device is already under development and will have the ability to capture additional vital parameters, including continuous blood pressure trends.

Everion® rounds out Biofourmis' Biovitals® ecosystem, a highly sophisticated personalized AI-powered predictive analytics platform that predicts clinical exacerbation in advance of a critical event. The multi-parameter physiology data captured from Everion® will be an integral component of Biovitals'® digital therapeutics products and pipeline to manage conditions such as heart failure, COPD, oncology and pain. These products are tailored to help providers identify the best therapies for managing chronic conditions before patients' health worsens, potentially reducing hospital readmissions and decreasing the need for emergency department visits to reduce costs.

"Biovotion had been a trusted partner for many years as we have leveraged each other's technologies across numerous clinical, commercial and research applications," said Kuldeep Singh Rajput, CEO and founder of Biofourmis. "We are thrilled to add Everion® to the Biovitals® ecosystem, which will continue to help our clients achieve their goals such as demonstrating the value of pharmacotherapy, managing chronic diseases, predicting and preventing adverse events, and improving clinical outcomes—and ultimately reducing healthcare costs."

A complete, integrated solution

The entire Biovotion team will be incorporated into the Biofourmis family under the name "Biofourmis AG" in Zürich, Switzerland. The team brings deep knowledge and insights for developing and launching cutting-edge clinical-grade wearables, as well as an impressive roster of more than 80 current and previous partners—including large global pharmaceutical companies and contract research organizations (CROs), healthcare providers such as Mayo Clinic and the University Hospital of Basel, and technology partners such as IBM Research and Microsoft.

"Our relationship with Biofourmis has been extremely beneficial over the years and in that time has grown in scope and depth, so joining forces made strategic sense for both our companies," said Dr. Markus Christen, Biovotion Chairman and CEO. "I am excited about what the future holds for our groundbreaking technology. Being part of the Biofourmis family will allow us to accelerate the development of our innovative platform to collect continuous vital data from patients. Certainly, providers, payers, managed care organizations and pharmaceutical companies will benefit tremendously from our synergies—but more importantly, this agreement will help more patients across the globe achieve optimal outcomes, which is most gratifying."

The future synergies created from this acquisition are many. Since they are worn comfortably on the upper arm, Everion® devices have achieved greater than 80% adherence rates among patients and study participants. The high patient adherence rate and accurate data collection of numerous clinical and non-clinical parameters are two of the primary reasons Biofourmis commonly uses the device for remotely monitoring patients to support patient care, commercial projects and clinical research with health systems, pharmaceutical companies, managed care organizations and FDA-funded entities.

Now that the Everion® and Biovitals® solutions are one, securing future clinical, pharmaceutical and other agreements will be more efficient and expedited, offering potential clients a single, experienced and proven digital therapeutics partner for all their needs.

"Biofourmis' powerful and predictive AI-driven Biovitals® ecosystem is now complete with the addition of Biovotions' high-fidelity, clinical-grade wearable Everion—and the extensive intellectual property for wearables and sensors that are part of this acquisition make Biofourmis the dominant player in this space," Rajput said. "The combined solution sets a new standard for the emerging digital therapeutics market that creates a compelling competitive advantage."

About Biofourmis

Biofourmis, a fast-growing global leader in digital therapeutics, discovers, develops and delivers clinically validated software-based therapeutics to provide better outcomes for patients, advanced tools for clinicians to deliver personalized care, technology to demonstrate the value of and potentially complement pharmacotherapy, and cost-effective solutions for payers. Biofourmis has built Biovitals®, a highly sophisticated personalized AI-powered health analytics platform that predicts clinical exacerbation in advance of a critical event, which is the backbone of their digital therapeutics product pipeline across multiple therapeutic areas, including heart failure, oncology, acute coronary syndrome, COPD and chronic pain.

For more information visit: www.biofourmis.com      

Media Contact:
Tara Stultz
Amendola Communications for Biofourmis
+1 440.225.9595
[email protected] 

SOURCE Biofourmis

Related Links

http://www.biofourmis.com

Modal title

Also from this source

Wise Health System Partners with Biofourmis for Continuum-Wide...

Wise Health System Partners with Biofourmis for Continuum-Wide...


Biofourmis Selected by American College of Cardiology as...

Biofourmis Selected by American College of Cardiology as...

Explore

More news releases in similar topics

  • Computer & Electronics
  • Computer Software
  • Health Care & Hospitals
  • Medical Equipment
  • Acquisitions, Mergers and Takeovers

Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2022 Cision US Inc.